What is ChipCare?
Leveraging technology developed at the University of Toronto, ChipCare is a point-of-care (POC) diagnostics company focused on bringing lifesaving diagnostics to underserved populations. The company's flagship product, the ChipCare PAx (Polyvalent Analyzer), is a portable, user-friendly multiplex reader designed to deliver lab-quality results in approximately 15 minutes. This is achieved through the use of low-cost microfluidic disposable cartridges, positioning ChipCare to disrupt traditional diagnostic workflows with accessible and rapid testing capabilities.
How much funding has ChipCare raised?
ChipCare has raised a total of $25.8M across 3 funding rounds:
Unspecified
$2M
Series A
$5M
Series B
$18.8M
Unspecified (2013): $2M with participation from MaRS Innovation and Maple Leaf Angels
Series A (2015): $5M led by MaRS Innovation, Maple Leaf Angels, and Epic Capital
Series B (2016): $18.8M supported by Biotech Alliances International
Key Investors in ChipCare
Biotech Alliances International
Biotech Alliances International is a Miami-based life science advisory firm specializing in strategic insights for biotechnology, pharmaceutical, and healthcare companies. They focus on capital raising, M&A, and strategic counseling, leveraging industry knowledge and a global network to connect innovators with capital and opportunities.
MaRS Innovation
MaRS Innovation is a leading commercialization service provider and early-stage funder, focused on bringing promising research breakthroughs from its 14 member institutions to market. They actively manage a portfolio of early-stage companies, driving commercialization through strategic partnerships and securing investment.
Maple Leaf Angels
Maple Leaf Angels is Toronto's largest angel investor network, supporting Canadian startups by investing in seed and early-stage technology companies. They provide capital alongside strategic guidance and mentorship, collaborating with entrepreneurs to foster business growth.
What's next for ChipCare?
The substantial enterprise-level backing ChipCare has received indicates a strong market validation and a strategic push towards scaling its operations and market penetration. With its focus on accessible POC diagnostics, the company is poised to address critical healthcare needs, particularly in remote or resource-limited settings. Future growth will likely involve expanding its product offerings, securing regulatory approvals, and forging strategic partnerships to broaden its reach. The recent strategic investment suggests a focus on accelerating commercialization and solidifying its position in the competitive diagnostics landscape.
See full ChipCare company page
